Guangzhou Baiyunshan Pharmaceutical (SHA:600332) said its subsidiary, Tianxin Pharmaceutical, received approval after its dexamethasone sodium phosphate injection passed China's generic drug quality and efficacy consistency evaluation, according to a Thursday filing with the Shanghai bourse.
The drug is used to treat allergic and autoimmune inflammatory diseases.
Shares of the pharmaceutical company rose nearly 1% in recent trade.